All stock lists
MercadoLibre, Inc. (NASDAQ:MELI)
UY · Delayed Price · Currency is USD
Also listed: MLB1.DE, 0K0E.LConsumer Cyclical · Specialty Retail
1668.72-141.43 (-7.81%)
Market cap
$84.6B
Insider Score
Health Score
Analyst consensus
Listed since
Aug 10, 2007
Website
Insider Score
––Not scored
MELI Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
MELI analyst forecast
MELI analyst consensus
Moderate Buy5 ratings
Buy 3 Hold 2 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
MELI 12-month price target
$2,662.50+59.5% upsideaverage of 4 firms
$2,900.00High
$2,400.00Low
MELI ratings mix, last 12 months
Buy Hold Sell
Best analysts covering MELI
- BTIG100%success rate · +32.9% avg return · 6 calls
- JP Morgan100%success rate · +31.8% avg return · 5 calls
- UBS100%success rate · +43.6% avg return · 3 calls
- Wedbush89%success rate · +30.9% avg return · 9 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
MELI analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Citigroup | Neutral | — | — | Reiterated | 2026-10-13 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-10-12 |
| Susquehanna | Positive | $2,400.00 | +29.0% | Reiterated | 2026-10-06 | |
| — | BTIG | Buy | — | — | Reiterated | 2026-09-03 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-08-11 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-08-06 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-06 |
| — | Citigroup | Neutral | — | — | Reiterated | 2026-07-15 |
| — | BTIG | Buy | — | — | Reiterated | 2026-06-02 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-05-13 |
| — | UBS | Neutral | — | — | Reiterated | 2026-05-13 |
| — | Citigroup | Neutral | — | — | Downgraded | 2026-05-13 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-05-11 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-11 |
| — | Benchmark | Buy | — | — | Reiterated | 2026-05-08 |
| — | BTIG | Buy | — | — | Reiterated | 2026-05-08 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2026-05-07 |
| — | UBS | Neutral | — | — | Downgraded | 2026-04-29 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-04-21 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-20 |
| — | BTIG | Buy | — | — | Reiterated | 2026-04-10 |
| — | Jefferies | Buy | — | — | Upgraded | 2026-04-07 |
| — | BTIG | Buy | — | — | Reiterated | 2026-03-20 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2026-03-12 |
| Morgan Stanley | Overweight | $2,600.00 | +46.9% | Reiterated | 2026-03-09 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-03-02 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-02-25 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-02-25 |
| — | BTIG | Buy | — | — | Reiterated | 2026-02-25 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-02-25 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-02-17 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2026-02-12 |
| — | BTIG | Buy | — | — | Reiterated | 2026-02-04 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-12-19 |
| — | BTIG | Buy | — | — | Reiterated | 2025-12-04 |
| UBS | Buy | $2,900.00 | +48.6% | Reiterated | 2025-11-24 | |
| — | BTIG | Buy | — | — | Reiterated | 2025-11-14 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-11-03 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-11-03 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-10-30 |
| — | Benchmark | Buy | — | — | Reiterated | 2025-10-30 |
| Cantor Fitzgerald | Overweight | $2,750.00 | +14.4% | Reiterated | 2025-10-30 | |
| — | Benchmark | Buy | — | — | Reiterated | 2025-10-21 |
| Barclays | Overweight | $2,800.00 | +33.2% | Reiterated | 2025-10-21 | |
| — | Susquehanna | Positive | — | — | Reiterated | 2025-10-13 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-10-09 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-10-03 |
| Cantor Fitzgerald | Overweight | $2,900.00 | +16.3% | Reiterated | 2025-09-24 | |
| — | Citigroup | Buy | — | — | Reiterated | 2025-08-18 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-08-07 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-08-05 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2025-08-05 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-08-05 |
| — | Jefferies | Hold | — | — | Reiterated | 2025-08-05 |
| — | Benchmark | Buy | — | — | Reiterated | 2025-08-05 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-07-23 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-07-17 |
| — | Susquehanna | Positive | — | — | Reiterated | 2025-06-26 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-06-11 |
MELI earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-10-29 | 9.12 | 8.32 | $7.22B | $7.41B |
| 2026-02-24 | 11.45 | 11.03 | $8.45B | $8.76B |
| 2026-05-07 | 8.75 | 8.23 | $8.29B | $8.85B |
| 2026-08-05 | 8.65 | 9.19 | $9.79B | $10.20B |
| 2026-11-04Upcoming | 9.34 | — | $10.69B | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.